# Immuno Oncology Assay Market

> Immuno-oncology Assay Market Research Report: Size, Share, Trend Analysis By Product (Reagents & Kits, Instruments) By Assay Type (Immune Cell Profiling Assays, Cytokine Release Assays, Tumor Mutation Burden Assays, Co-Culture Assays, Cytotoxicity Assays, Others) By Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, PCR-based Techniques, Next-Generation Sequencing (NGS), Mass Cytometry, Others) By Applications (Cancer Diagnosis, Therapeutic Monitoring, Patient Stratification, Clinical Trials) By Indication (Lung Cancer, Colorectal Cancer, Melanoma, Ovarian Cancer, Breast Cancer, Others) By End Users (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.92%
- **2024:** $ 3,954.87 Million
- **2025:** $ 4,399.79 Million
- **2035:** $ 12,406.18 Million
- **Key Players:** THERMO Fisher Scientific Inc, Qiagen, Merck KGAA, Sartorius Ag, F. Hoffmann-La Roche Ltd., and Agilent Technologies Inc.

**Report ID:** MRFR/HC/41291-CR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** June 29, 2026

**URL:** https://www.marketresearchfuture.com/reports/immuno-oncology-assay-market-42957

---

## Market Summary

## **Immuno-Oncology Assay Market Overview**

As per MRFR analysis, the Immuno-Oncology Assay Market Size was estimated at 28.01 (USD Billion) in 2023. The Immuno-Oncology Assay Market Industry is expected to grow from 29.4 (USD Billion) in 2024 to 50.0 (USD Billion) by 2035. The Immuno-Oncology Assay Market CAGR (growth rate) is expected to be around 4.94% during the forecast period (2025 - 2035).

## **Key Immuno-Oncology Assay Market Trends Highlighted**

The Global Immuno-Oncology Assay Market is experiencing significant growth driven by several key factors. The rise in cancer prevalence worldwide and the increasing demand for personalized medicine are primary market drivers. Advances in technology and research have led to the development of new assays that enhance the ability to tailor treatments to individual patients.

Furthermore, the growing focus on early cancer detection and the increasing investment in research and development by pharmaceutical companies are also contributing to market expansion. These factors are creating a robust landscape for growth in immuno-oncology assays.

Opportunities within this market are becoming more pronounced, especially with the increasing adoption of companion diagnostics. As more therapies are developed, the need for effective assays to identify suitable patient populations will grow. Additionally, collaboration between biotech firms and pharmaceutical companies is likely to yield innovative solutions that can improve outcomes for cancer patients.

Expanding regulatory approvals for immuno-oncology products also present avenues for market participants to enhance their product offerings and reach broader patient populations. Companies that can harness these opportunities may position themselves as leaders in this evolving space.

In recent times, trends such as the integration of artificial intelligence in assay development and an emphasis on biomarker research have emerged. This integration is streamlining the process of assay identification and validation, enabling quicker turnaround times for results.

There is also a growing movement towards the standardization of assays to ensure consistency across different platforms and laboratories. As the market continues to mature, a focus on improving patient outcomes while minimizing costs will be paramount. Overall, the Global Immuno-Oncology Assay Market is poised for dynamic growth driven by innovation, collaboration and a commitment to enhancing cancer care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Immuno-Oncology Assay Market Drivers**

### **Increasing Prevalence of Cancer Worldwide**

The rise in cancer incidence globally serves as a significant driver for the Global Immuno-Oncology Assay Market Industry. Cancer, being one of the leading causes of death, continues to affect millions of individuals across various demographics, leading to a surging demand for effective diagnostics and treatment options. Immuno-oncology assays play a crucial role in identifying specific biomarkers, thereby aiding in the development and implementation of personalized treatment regimens.

This shift towards tailored treatments is largely a response to patients' unique genetic and molecular profiles, which vary significantly. As more researchers and healthcare providers recognize the potential of immunotherapy, investments in immuno-oncology research are projected to increase, resulting in the creation of innovative assays that can offer diverse and effective treatment pathways. Moreover, advancements in technology and increased understanding of cancer biology have made it clear that early detection and appropriate monitoring are essential for improving patient outcomes.

In an attempt to advance the search for better screening tools, patients and physicians alike are contributing to the anticipated healthy growth of the Global Immuno-Oncology Assay Market, which mirrors increased attempts to fight cancer via precision medicine and targeted therapy approaches.

### **Technological Advancements in Diagnostics**

The consistent advancements in technology significantly propel the Global Immuno-Oncology Assay Market Industry. With the ongoing development of more sophisticated diagnostic tools, including next-generation sequencing (NGS) and high-throughput screening methods, the capacity for accurate and rapid testing has markedly improved.

These innovations empower clinicians to make more informed decisions, enhancing the speed and efficiency of cancer diagnostics.Consequently, this trend is driving the demand for novel immuno-oncology assays designed to provide actionable insights for personalized treatment approaches, thus fostering a robust growth trajectory for the market.

### **Rising Investment in Cancer Research and Development**

An increase in investments directed toward cancer research and development fuels growth in the Global Immuno-Oncology Assay Market Industry. As pharmaceutical companies, governmental bodies, and non-profit organizations recognize the critical need for innovative cancer therapies, funding for research initiatives has surged.

This financial support significantly enhances the exploration and validation of new immuno-oncology assays, paving the way for groundbreaking advancements in cancer treatment.

The collaborative efforts among stakeholders in the healthcare space, including academic institutions and biotechnology firms, further amplify the pace of innovation, enabling the development of more effective diagnostic tools that are essential for personalized medicine.

## **Immuno-Oncology Assay Market Segment Insights**

### **Immuno-Oncology Assay Market Assay Type Insights**

The Global Immuno-Oncology Assay Market is witnessing substantial growth driven by its diverse assay type offerings such as Immune Cell Profiling Assays, Cytokine Release Assays, Tumor Mutation Burden Assays, and Biomarker Discovery Assays. In 2024, the overall market is expected to be valued significantly, reflecting a robust landscape for immuno-oncology research and testing, particularly with the rising demand for personalized medicine.

Among these assay types, Immune Cell Profiling Assays hold a major position with a valuation of 7.0 USD Billion, which is projected to rise to 12.0 USD Billion by 2035. This growth can be attributed to their critical role in understanding and assessing the immune system's response to cancer therapies, allowing for more targeted and effective treatment options.

Cytokine Release Assays also play a significant part in this space, with an expected value of 6.5 USD Billion in 2024, increasing to 11.0 USD Billion by 2035. These assays are vital for evaluating immune responses, especially in the context of immunotherapy, thereby enhancing our comprehension of the underlying mechanisms of action in cancer treatment.

The Tumor Mutation Burden Assays are poised for noteworthy expansion with a valuation of 8.0 USD Billion in 2024, projected to reach 13.0 USD Billion by 2035. This assay’s importance lies in its ability to quantify the number of mutations within the cancer genome, providing critical insights into tumor behavior and treatment responsiveness, as well as enabling stratified patient management.

Biomarker Discovery Assays contribute significantly as well, with a current valuation of 7.9 USD Billion expected to grow to 14.0 USD Billion by 2035, indicating a robust growth trajectory. These assays are essential for identifying new biomarkers that can predict patient responses to therapies, guiding clinicians toward more precise therapeutic strategies.

Overall, the segmentation within the Global Immuno-Oncology Assay Market showcases a rich tapestry of assay types, each playing a pivotal role in advancing our understanding and treatment of cancers through innovative testing methods. The trend towards personalized medicine and the increasing prevalence of cancer worldwide are expected to dominate the landscape, driving market growth as healthcare systems increasingly adopt these advanced assay technologies for better patient outcomes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Immuno-Oncology Assay Market Technology Insights**

This market encompasses various technology-driven approaches, including Enzyme-Linked Immunosorbent Assay, Flow Cytometry, PCR-based Techniques, and Next Generation Sequencing, which are essential for understanding and treating cancer effectively. The Enzyme-Linked Immunosorbent Assay technology is pivotal for its high-throughput screening capabilities, while Flow Cytometry dominates in cell analysis and provides detailed insights into the tumor microenvironment. PCR-based Techniques are increasingly significant due to their precision in detecting genetic alterations, and Next Generation Sequencing offers comprehensive genomic profiling, thus enabling personalized medicine strategies in immuno-oncology.

These technologies together form a crucial foundation in the Global Immuno-Oncology Assay Market, as their advancements drive efficiency and accuracy in cancer diagnostics and research, reflecting the evolving landscape of cancer treatment methodologies. The integration of these technologies indicates a focused approach toward improving patient outcomes and unlocking new therapeutic avenues.

### **Immuno-Oncology Assay Market Application Insights**

The Global Immuno-Oncology Assay Market is expected to see robust growth in its Application segment, particularly as the demand for advanced diagnostic and therapeutic solutions rises. Within the Application market, Cancer Diagnosis plays a crucial role in enabling early intervention through enhanced biomarker identification, contributing significantly to the overall market revenue. Therapeutic Monitoring is equally important, as it helps in assessing treatment efficacy and adjusting therapies accordingly.

Patient Stratification is pivotal for personalizing treatment plans, ensuring that patients receive the most suitable therapies, while Clinical Trials leverage these assays for efficient drug development and validation processes. The growth drivers in this segment include rising cancer prevalence, increased healthcare expenditure, and advancements in laboratory technologies. However, challenges such as regulatory hurdles and the high cost of assays can impact growth trajectories. Overall, the segment reflects a promising landscape with ample opportunities as healthcare systems continue to prioritize innovative diagnostic and therapeutic strategies in fighting cancer.

### **Immuno-Oncology Assay Market End Use Insights**

The segmentation within the End Use sector includes Hospitals, Clinical Laboratories, Research Institutions, and Pharmaceutical Companies, all playing critical roles. Hospitals serve as primary hubs for patient treatment and diagnosis, making them a major component of this market. Clinical Laboratories are essential for conducting assays that support clinical decisions and are vital for both routine and complex testing.

Research Institutions are increasingly important as they drive innovation in immuno-oncology through extensive studies and clinical trials, facilitating the development of new therapeutic approaches. Meanwhile, Pharmaceutical Companies hold a significant position by integrating assay technologies into drug development processes, underscoring their importance in bringing new treatments to market. The overall growth of the market is fueled by a combination of increasing cancer prevalence, technological advancements, and a growing emphasis on effective therapeutic strategies. As these factors continue to evolve, the Global Immuno-Oncology Assay Market is poised for steady progress in the years ahead.

### **Immuno-Oncology Assay Market Regional Insights**

The Global Immuno-Oncology Assay Market exhibits significant regional diversity, with North America leading the landscape, projected to reach a valuation of 15.0 USD Billion in 2024 and 25.0 USD Billion by 2035, underscoring its majority holding within the market. Following this, Europe demonstrates a substantial presence, with values of 7.5 USD Billion in 2024 and an expected rise to 12.0 USD Billion by 2035, highlighting its significant contribution and advanced research initiatives in this field.

In contrast, the APAC region shows a promising growth trajectory with a valuation of 4.0 USD Billion in 2024, projected to double by 2035 to 8.0 USD Billion, emphasizing its increasing investment in immuno-oncology solutions. South America, with a value of 2.0 USD Billion in 2024 to 3.5 USD Billion by 2035, remains a developing market, presenting opportunities for expansion and collaboration.

Lastly, the MEA segment, valued at 1.9 USD Billion in 2024, experiences challenges for growth as its valuation indicates a decline to 1.5 USD Billion by 2035. Overall, these insights into the Global Immuno-Oncology Assay Market segmentation reveal the dynamic interplay of regional strengths and potential as the industry evolves.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **Immuno-Oncology Assay Market Key Players and Competitive Insights**

The Global Immuno-Oncology Assay Market has become increasingly crucial in the landscape of cancer treatment, serving as a vital component in understanding tumor behavior and patient-specific responses to immunotherapies. A range of players are involved in this market, which facilitates competition among established pharmaceutical companies, biotechnology firms, and diagnostic service providers.

These competitive insights reflect an ecosystem where innovation drives growth, and technology advancements bolster the development of various assays that are essential for determining the efficacy of immuno-oncology therapies. As the demand for personalized medicine rises, organizations that can harness advanced analytics, genomic profiling, and biomarker discovery will likely emerge as leaders in this fast-evolving market, showcasing a dynamic interplay of competitive strategies aimed at securing market share and addressing unmet clinical needs in oncology.

Amgen has carved out a significant space for itself in the Global Immuno-Oncology Assay Market by leveraging its extensive research capabilities and solid understanding of molecular pathways associated with immune responses in tumors. The company's strong portfolio of innovative therapies is complemented by its commitment to advancing companion diagnostics, which are essential for the tailored use of immunotherapies in clinical practice.

With robust financial backing and a history of strategic partnerships, Amgen can invest heavily in research and development, propelling forward its capabilities in assay development. This positions the company favorably within the market as the ability to provide precise and actionable insights via advanced assays becomes more critical. Furthermore, Amgen's emphasis on regulatory compliance and securing necessary approvals for their assays anchors their strength, enhancing their market presence and trustworthiness in the field.

Merck is another vital player in the Global Immuno-Oncology Assay Market, recognized for its substantial contributions to drug development and diagnostics. The company has successfully built strong relationships within healthcare ecosystems that facilitate access to cutting-edge technologies in immuno-oncology. Merck's focus on integrating diagnostics with therapeutic options enables personalized treatment approaches, highlighting its dual expertise in developing effective immunotherapies and corresponding assays.

The firm's investment in clinical trials, combined with a robust pipeline of innovative immuno-oncology products, further consolidates its standing as a formidable competitor in this space. Merck's strong emphasis on scientific research and collaboration with academic institutions enhances its potential to stay ahead of trends while addressing the evolving needs and challenges in the landscape of cancer treatment through improved assays.

### **Key Companies in the Immuno-Oncology Assay Market Include**

- Amgen
- Merck
- **[Pfizer](https://www.pfizer.com/products/product-list)**
- Bristol Myers Squibb
- PerkinElmer
- Agilent Technologies
- AbbVie
- Qiagen
- Thermo Fisher Scientific
- Novartis
- Illumina
- Sanofi
- Roche
- Eli Lilly
- GSK

## Immuno Oncology Assay Market Industry Developments

- **Q2 2024: Personalis Launches NeXT Personal Dx, a Tumor-Informed, Ultra-Sensitive MRD Assay for Solid Tumors** Personalis announced the launch of NeXT Personal Dx, a tumor-informed, ultra-sensitive minimal residual disease (MRD) assay for solid tumors, expanding its immuno-oncology assay portfolio.
- **Q2 2024: Guardant Health Announces FDA Approval of Guardant360 CDx as a Companion Diagnostic for KRAZATI in Non-Small Cell Lung Cancer** Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy assay as a companion diagnostic for KRAZATI, supporting immuno-oncology treatment decisions in non-small cell lung cancer.
- **Q2 2024: NeoGenomics Launches RaDaR Assay for MRD Detection in Solid Tumors** NeoGenomics announced the commercial launch of its RaDaR assay, designed for minimal residual disease detection in solid tumors, enhancing its immuno-oncology assay offerings.
- **Q2 2024: Bio-Techne and Regeneron Announce Strategic Partnership to Develop Companion Diagnostics for Immuno-Oncology Therapies** Bio-Techne and Regeneron Pharmaceuticals entered a strategic partnership to co-develop companion diagnostics supporting Regeneron's immuno-oncology pipeline.
- **Q3 2024: Roche launches new immuno-oncology assay to support clinical trials** Roche launched a new immuno-oncology assay aimed at supporting pharmaceutical clinical trials, expanding its diagnostics portfolio for cancer immunotherapy.
- **Q3 2024: Agilent Technologies Receives FDA Approval for PD-L1 IHC 22C3 pharmDx as a Companion Diagnostic in Cervical Cancer** Agilent Technologies received FDA approval for its PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic for immunotherapy in cervical cancer.
- **Q3 2024: Caris Life Sciences Announces Opening of New Liquid Biopsy Laboratory to Expand Immuno-Oncology Testing** Caris Life Sciences opened a new liquid biopsy laboratory to expand its immuno-oncology assay capabilities, supporting advanced cancer diagnostics.
- **Q4 2024: Illumina and Merck Expand Partnership to Develop Next-Generation Sequencing-Based Companion Diagnostics for Immuno-Oncology** Illumina and Merck expanded their partnership to develop next-generation sequencing-based companion diagnostics for immuno-oncology therapies.
- **Q4 2024: Thermo Fisher Scientific Launches Oncomine Immune Response Assay for Research Use** Thermo Fisher Scientific launched the Oncomine Immune Response Assay, designed to profile immune-related gene expression in cancer research.
- **Q1 2025: Grail Announces New Partnership with AstraZeneca to Develop Blood-Based Immuno-Oncology Assays** Grail and AstraZeneca announced a partnership to co-develop blood-based immuno-oncology assays for early cancer detection and therapy selection.
- **Q1 2025: Natera Receives CE Mark for Signatera MRD Assay in Colorectal Cancer** Natera received CE Mark approval for its Signatera minimal residual disease (MRD) assay for use in colorectal cancer, supporting immuno-oncology clinical applications in Europe.
- **Q2 2025: Foundation Medicine Announces FDA Approval of FoundationOne CDx as a Companion Diagnostic for New Immunotherapy** Foundation Medicine received FDA approval for its FoundationOne CDx assay as a companion diagnostic for a newly approved immunotherapy, expanding its role in precision oncology.

## **Immuno-Oncology Assay Market Segmentation Insights**

### **Immuno-Oncology Assay Market Assay Type Outlook**

- Immune Cell Profiling Assays
- Cytokine Release Assays
- Tumor Mutation Burden Assays
- Biomarker Discovery Assays

### **Immuno-Oncology Assay Market Technology Outlook**

- Enzyme-Linked Immunosorbent Assay
- [Flow Cytometry](../../../reports/flow-cytometry-market-6433)
- PCR-based Techniques
- Next Generation Sequencing

### **Immuno-Oncology Assay Market Application Outlook**

- Cancer Diagnosis
- Therapeutic Monitoring
- Patient Stratification
- Clinical Trials

### **Immuno-Oncology Assay Market End Use Outlook**

- Hospitals
- Clinical Laboratories
- Research Institutions
- Pharmaceutical Companies

### **Immuno-Oncology Assay Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Incidence of Cancer

The rising global incidence of cancer has become a critical public health challenge, driven by a convergence of factors including increased life expectancy, urbanization, dietary changes, tobacco use, environmental pollution, and sedentary lifestyles. As cancer cases continue to rise, the complexity and heterogeneity of tumors necessitate advanced diagnostic tools that extend beyond conventional methods.
 
According to the Global Cancer Observatory, the estimated number of new cancer cases between 2022 and 2025, across both sexes and all cancer types, is as follows: Asia – 9,826,539; Europe – 4,471,422; Northern America – 2,850,879; Latin America and the Caribbean – 1,629,786; Africa – 1,301,241; and Oceania – 293,175.

### Technological Advancements

Rapid technological advancements in immunohistochemistry (IHC) and biomarker development are creating lucrative growth opportunities in the global immuno-oncology assay market. For instance, in February 2020, Biocare Medical’s launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This product expansion includes several cutting-edge immuno-oncology markers that are instrumental in accelerating early-stage cancer drug development and improving patient stratification for targeted therapies. Among these innovations is the redevelopment of the S100 protein antibody, which is widely used in the detection of Schwannomas, ependymomas, astrogliomas, and nearly all benign and malignant melanomas. Biocare’s enhanced version, S100, offers a significantly stronger and more robust staining signal, improving the sensitivity and accuracy of IHC applications. Such technological breakthroughs not only enhance diagnostic precision but also support the growing demand for personalized oncology solutions driving market expansion and attracting investment across diagnostics, biotech, and pharmaceutical sectors.

### Growing Investment in Cancer Research

The surge in investment directed towards cancer research is a significant catalyst for the Immuno-Oncology Assay Market. Governments and private entities are increasingly allocating funds to explore innovative cancer therapies, particularly in immunotherapy. This financial support fosters the development of advanced immuno-oncology assays, which are essential for evaluating the efficacy of new treatments. As research initiatives expand, the demand for reliable and efficient assays is likely to grow, further propelling the market. The emphasis on collaborative research efforts among academic institutions, pharmaceutical companies, and biotechnology firms enhances the potential for breakthroughs in cancer treatment, thereby benefiting the Immuno-Oncology Assay Market.

### Rising Demand for Companion Diagnostics

The increasing demand for companion diagnostics is a pivotal driver for the Immuno-Oncology Assay Market. Companion diagnostics are essential for determining the suitability of specific therapies for individual patients, particularly in the context of immunotherapy. As healthcare providers strive to offer personalized treatment options, the need for reliable assays that can guide therapeutic decisions becomes paramount. The integration of companion diagnostics into clinical practice not only enhances patient outcomes but also drives the adoption of immuno-oncology assays. This trend is likely to result in a more tailored approach to cancer treatment, further solidifying the role of the Immuno-Oncology Assay Market in modern oncology.

### Government and Private Funding for Cancer Research

Robust government and private sector funding for cancer research is significantly accelerating the growth of the global immuno-oncology (I-O) assay market. Large-scale investments by national health agencies and private foundations are fueling innovation in cancer diagnostics and personalized therapies. These funds support biomarker discovery, clinical trials, and the development of cutting-edge diagnostic platforms—including I-O assays—that enable precise patient stratification and therapy monitoring. For example, the Government of India has taken significant steps toward combating cancer and enhancing public health, allocating $1.20 billion (₹99,858.56 crore) to the Ministry of Health and Family Welfare in the recent budget. Of this, $1.15 billion (₹95,957.87 crore) is earmarked for the Department of Health and Family Welfare, and $47 million (₹3,900.69 crore) for the Department of Health Research. Among the notable initiatives is the plan to establish 200 Day Care Cancer Centres in district hospitals by 2025–26, significantly improving access to oncology services in underserved regions. To further support cancer care and the treatment of rare and chronic diseases, the government has introduced customs duty exemptions. A total of 36 life-saving drugs have been exempted from Basic Customs Duty (BCD), while six essential medicines now benefit from a concessional duty rate of 5%.

## Future Outlook

The Immuno-oncology Assay Market is projected to grow at a 10.92% CAGR from 2025 to 2035, driven by growing geriatric population and technological advancements.

**New opportunities:**

- Expansion of companion diagnostics for emerging immunotherapies Increased adoption of decentralized and point-of-care immune monitoring Opportunities in assays supporting personalized cancer vaccines Growth in biomarker discovery for combination immunotherapies Expansion into APAC with rising clinical trial activity

By 2035, the market is expected to achieve substantial growth, reflecting its critical role in cancer treatment.

## Segment Insights

### By Type: Immune Cell Profiling Assays (Largest) vs. Cytokine Release Assays (Fastest-Growing)

The Immuno-Oncology Assay Market is characterized by diverse segment values, each contributing significantly to overall growth. Immune Cell Profiling Assays have established themselves as the largest segment, dominating the market due to their critical role in assessing the immune response in cancer patients. Conversely, Cytokine Release Assays have emerged as the fastest-growing segment, driven by increasing demand for precision medicine and tailored immunotherapies. Growth trends reveal a shift towards personalized cancer treatment approaches, which significantly boost the demand for these assays. The rising prevalence of cancer and continuous advancements in technology are major drivers enhancing the adoption of Tumor Mutation Burden Assays and Biomarker Discovery Assays. As research increases around immune responses and tumor interactions, these assays will see substantial growth in applications across clinical settings.

Immune Cell Profiling Assays (Dominant) vs. Biomarker Discovery Assays (Emerging)

Immune Cell Profiling Assays represent a dominant force within the Immuno-Oncology Assay Market, primarily because of their capability to provide deep insights into the immune landscape of tumors. These assays aid researchers in identifying specific immune cell types and their functionalities, informing treatment decisions and therapeutic strategies. In contrast, Biomarker Discovery Assays are an emerging segment that focuses on identifying new molecular targets for therapy. The rise of precision oncology fuels this growth, as these assays play a pivotal role in the discovery and validation of biomarkers for targeted treatments, creating a pathway for innovation in personalized cancer therapy.

### By Technology: Enzyme-Linked Immunosorbent Assay (Largest) vs. Next Generation Sequencing (Fastest-Growing)

The Immuno-Oncology Assay Market is characterized by diverse technologies, with Enzyme-Linked Immunosorbent Assay (ELISA) holding the largest market share. Flow Cytometry and PCR-based Techniques also contribute significantly to the overall landscape, yet it is ELISA that solidifies its position as a staple due to its established reliability in quantifying immune responses. Meanwhile, Next Generation Sequencing (NGS) is rapidly gaining traction, driven by its high throughput capabilities and ability to provide detailed genomic information critical for personalized treatment approaches.

Technology: ELISA (Dominant) vs. NGS (Emerging)

Enzyme-Linked Immunosorbent Assay (ELISA) remains the dominant force in the Immuno-Oncology Assay Market due to its robust methodology and extensive validation across clinical applications. It is pivotal for evaluating immune responses and therapeutic efficacy. In contrast, Next Generation Sequencing (NGS) is emerging as a critical tool, offering unprecedented insights into tumor genomics and aiding in precision medicine. NGS caters to the increasing demand for personalized therapy by enabling comprehensive profiling of tumors, thus positioning itself as a revolutionary player set to redefine therapeutic standards.

### By Application: Cancer Diagnosis (Largest) vs. Therapeutic Monitoring (Fastest-Growing)

In the Immuno-Oncology Assay Market, Cancer Diagnosis holds the largest share due to its critical role in the early detection and effective management of cancer. This segment is essential for determining the presence of specific biomarkers that influence treatment decisions and patient outcomes. Therapeutic Monitoring, while smaller in share, is rapidly increasing in importance as ongoing assessment of treatment efficacy continues to be a priority for oncology specialists. This growing emphasis on personalized medicine is driving the expanded use of assays to customize treatment regimens. The growth of these segments is influenced greatly by advancements in technology and a surge in research around immuno-oncology therapies. The push towards precision medicine directly correlates with the rising demand for effective diagnostic tools that not only identify cancer but also monitor patient responses to therapies, ensuring timely adjustments can be made. Additionally, increased funding for clinical research and the adoption of innovative biomarker assays are fueling advancements and driving expansion in the therapeutic monitoring sector.

Cancer Diagnosis (Dominant) vs. Patient Stratification (Emerging)

The Cancer Diagnosis segment represents a dominant force in the Immuno-Oncology Assay Market, characterized by its proven efficacy in identifying malignancies through advanced biomarkers. This segment's established methods and protocols have garnered widespread acceptance among healthcare professionals, reinforcing its market presence. In contrast, Patient Stratification is an emerging segment of increasing interest, as it focuses on tailoring treatments based on individual patient characteristics identified through immuno-oncology assays. By leveraging genomic and proteomic data, this approach enhances treatment outcomes and facilitates the development of more targeted therapies. As healthcare transitions to a more personalized approach, Patient Stratification is gaining traction, although it still faces challenges in wider adoption compared to the well-entrenched Cancer Diagnosis segment.

### By End Use: Hospitals (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

In the Immuno-Oncology Assay Market, hospitals hold a significant market share, serving as a primary end user due to their comprehensive cancer treatment facilities. They are equipped with state-of-the-art technology, which enables them to utilize advanced assays for patient diagnosis and treatment monitoring. In contrast, pharmaceutical companies are emerging as the fastest-growing segment as they invest heavily in research and development of novel therapies and assays, seeking to leverage immuno-oncology innovations for clinical trials and drug approvals.

Hospitals (Dominant) vs. Pharmaceutical Companies (Emerging)

Hospitals are the dominant end-users in the Immuno-Oncology Assay Market, leveraging their extensive patient access and advanced technological capabilities to implement rigorous testing protocols. They utilize a range of immuno-oncology assays to guide treatment decisions, making them integral to patient care pathways. Conversely, pharmaceutical companies are rapidly emerging within this market segment, driven by the need for innovative assay solutions to support their clinical development programs. They focus on creating targeted therapies and diagnostics, and their growing collaboration with research institutions enhances their position, as they aim to expedite drug discovery and regulatory approvals through advanced assay technologies.

### By Indication: lung cancer (Largest) vs. melanoma (Fastest-Growing)

Based on Indication, the global immuno-oncology assay market has been segmented into Lung Cancer, Colorectal Cancer, Melanoma, Ovarian Cancer, Breast Cancer, and Others. The lung cancer segment held the largest market share in 2024, and the melanoma segment is the fastest-growing segment during the forecast period (2025 -2035).

As the most prevalent cancer worldwide, lung cancer affects approximately 2.1 billion individuals annually and is responsible for an estimated 1.7 billion deaths each year. It remains the leading cause of cancer-related mortality for both men and women globally. In the United States alone, 2023 saw an estimated 240,000 new cases of lung cancer and around 130,000 associated deaths, underscoring its substantial health burden. Lung cancer's lethality surpasses that of breast, prostate, and colon cancers combined. The disease is broadly classified into two main types: small cell lung cancer (SCLC), which accounts for approximately 10-15% of all lung cancer cases, and non-small cell lung cancer (NSCLC), representing about 85-90% of cases. Immuno-oncology assays play a crucial role in understanding and targeting these mechanisms by analyzing key immune biomarkers and cellular interactions within the tumor microenvironment. These assays evaluate factors such as PD-L1 expression levels, tumor mutational burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating lymphocytes (TILs). For Instance, in October 2024, China’s National Medical Products Administration (NMPA) has granted marketing approval for LungCure CDx, a next-generation sequencing (NGS)–based companion diagnostic designed to guide the use of sunvozertinib (DZD9008) in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC). This approval is a significant milestone in the field of immuno-oncology and [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925), as it marks the first NGS-based companion diagnostic co-developed and approved under China’s updated companion diagnostic guidelines.

### By End User: Hospitals & Clinics (Largest) vs. contract research organizations (CROs) (Fastest-Growing)

Based on End User, the Global immuno-oncology assay market has been segmented into Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others. The hospitals & clinics segment held the largest market share in 2024, and the contract research organizations (CROs) segment is the fastest-growing segment during the forecast period (2025 -2035).

Hospitals and clinics represent important end-user sectors in the Immuno-oncology Assay Market, with each playing a crucial role in its continued expansion. Hospitals and clinics represent critical end-user sectors in the immuno-oncology assay market due to their central role in cancer diagnosis, treatment planning, and patient management. As the demand for precision oncology continues to grow, hospitals and clinics are increasingly investing in advanced diagnostic platforms, making them key drivers of market expansion.

### By Technology: PCR-based techniques vs. next-generation sequencing (NGS): Emerging

On the basis of technology, the global immuno-oncology assay market is segmented Enzyme-Linked Immunosorbent Assay, Flow Cytometry, PCR-based Techniques, Next-Generation Sequencing (NGS), Mass Cytometry, Others. The PCR-based techniques segment dominated the market in 2024, while the next-generation sequencing (NGS) segment is projected to be the fastest-growing segment during the forecast period, 2025–2035
 
The Enzyme-Linked Immunosorbent Assay (ELISA) is a prominent analytical approach in immuno-oncology for quantitative detection of cytokines, chemokines, growth factors, and other immune-related proteins in a variety of [biological](https://www.marketresearchfuture.com/reports/biologics-market-1339)materials. It is critical for evaluating immune activation, monitoring tumor microenvironment alterations, and determining pharmacodynamic responses to immunotherapy. From a development and regulatory perspective, ELISA is a cost-effective, scalable, and reproducible assay that supports both early discovery and clinical biomarker programs. It is often used in conjunction with other immunoassays and cellular assays to build a comprehensive immune response profile. As immuno-oncology continues to advance, ELISA remains a core platform for biomarker validation and therapeutic monitoring, supporting data-driven decisions in both preclinical and clinical stages.

### By Application: cancer diagnosis vs. clinical trials (Fastest-Growing)

Based on Application, the Global immuno-oncology assay market has been segmented into Cancer Diagnosis, Therapeutic Monitoring, Patient Stratification, and Clinical Trials. The cancer diagnosis segment held the largest market share in 2024, and the clinical trials segment is the fastest-growing segment during the forecast period (2025 -2035).
 
Cancer diagnosis is a multifaceted process aimed at detecting and understanding the nature of cancer in a patient. It typically involves a combination of screening methods, imaging techniques (like CT scans or MRIs), tissue biopsies, and molecular testing to identify the type, stage, and genetic makeup of the tumor.

### By Indication: lung cancer (Largest) vs. melanoma (Fastest-Growing)

Based on Indication, the global immuno-oncology assay market has been segmented into Lung Cancer, Colorectal Cancer, Melanoma, Ovarian Cancer, Breast Cancer, and Others. The lung cancer segment held the largest market share in 2024, and the melanoma segment is the fastest-growing segment during the forecast period (2025 -2035).

As the most prevalent cancer worldwide, lung cancer affects approximately 2.1 billion individuals annually and is responsible for an estimated 1.7 billion deaths each year. It remains the leading cause of cancer-related mortality for both men and women globally. In the United States alone, 2023 saw an estimated 240,000 new cases of lung cancer and around 130,000 associated deaths, underscoring its substantial health burden. Lung cancer's lethality surpasses that of breast, prostate, and colon cancers combined. The disease is broadly classified into two main types: small cell lung cancer (SCLC), which accounts for approximately 10-15% of all lung cancer cases, and non-small cell lung cancer (NSCLC), representing about 85-90% of cases. Immuno-oncology assays play a crucial role in understanding and targeting these mechanisms by analyzing key immune biomarkers and cellular interactions within the tumor microenvironment. These assays evaluate factors such as PD-L1 expression levels, tumor mutational burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating lymphocytes (TILs). For Instance, in October 2024, China’s National Medical Products Administration (NMPA) has granted marketing approval for LungCure CDx, a next-generation sequencing (NGS)–based companion diagnostic designed to guide the use of sunvozertinib (DZD9008) in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC). This approval is a significant milestone in the field of immuno-oncology and precision medicine, as it marks the first NGS-based companion diagnostic co-developed and approved under China’s updated companion diagnostic guidelines.

### By End User: Hospitals & Clinics (Largest) vs. contract research organizations (CROs) (Fastest-Growing)

Based on End User, the Global immuno-oncology assay market has been segmented into Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others. The hospitals & clinics segment held the largest market share in 2024, and the contract research organizations (CROs) segment is the fastest-growing segment during the forecast period (2025 -2035).

Hospitals and clinics represent important end-user sectors in the Immuno-oncology Assay Market, with each playing a crucial role in its continued expansion. Hospitals and clinics represent critical end-user sectors in the immuno-oncology assay market due to their central role in cancer diagnosis, treatment planning, and patient management. As the demand for precision oncology continues to grow, hospitals and clinics are increasingly investing in advanced diagnostic platforms, making them key drivers of market expansion.

## Regional Market Share Analysis

**North America: increased prevalence of cancer**

North America is the largest market for Immuno-oncology Assay services, holding approximately 42% of the global market share. The region's growth is driven by increased prevalence of cancer, combined with the increasing use of immunotherapies such as immune checkpoint inhibitors and CAR-T cell treatments, has resulted in a strong demand for better diagnostic solutions. According to National Institute of Health, in 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are expected in the United States. Immuno-oncology assays are critical for finding biomarkers that drive individualized treatment, allowing clinicians to modify medicines based on unique patient profiles. The industry is also being boosted by an increasing emphasis on precision medicine, which stresses the use of biomarkers such as PD-L1, TMB, and MSI for more targeted and effective cancer treatments.

**Europe : Emerging Cloud Market**

Europe is witnessing a significant rise in the Immuno-oncology Assay market, accounting for approximately 30% of the global share. The region's growth is driven by a number of factors such as rising cancer rates, rapid advances in immunotherapy, and increased investments in customized medicine. According to the World Health Organization (WHO), cancer is still the second biggest cause of death in Europe, with more than 3.7 million new cases projected by 2025. The increase in cancer cases is creating a substantial demand for precise diagnostic tools, such as immuno-oncology assays.

Furthermore, the European Union's Horizon 2020 initiative has given more than USD 1.71 billion to cancer research, demonstrating the continent's commitment to improving cancer care and diagnostics. Immuno-oncology tests, which detect biomarkers such as PD-L1, Tumor Mutational Burden (TMB), and Microsatellite Instability (MSI), play an important role in directing the selection of immunotherapies such as immune checkpoint inhibitors and CAR-T cells.  The European Medicines Agency (EMA) has authorized many immuno-oncology medications and companion diagnostics, notably Merck's Keytruda (pembrolizumab) for a variety of cancer indications, increasing demand for biomarker-based testing.

**Asia-Pacific: Rapidly Growing Cloud Sector**

Asia-Pacific is rapidly emerging as a key player in the Immuno-oncology Assay market, holding around 20% of the global market share. The immuno-oncology assay market in Asia-Pacific (APAC) is expanding rapidly, owing to a combination of factors such as rising cancer rates, advances in immunotherapy, and considerable investments in healthcare infrastructure. For instance, according to the National Center for Disease Informatics and Research, lung, colorectal, and liver cancers are prevalent in nations such as China and India. For example, the cancer burden in India is expected to increase from 26.7 million disability-adjusted life years (DALYs) in 2021 to 29.8 million by 2025.

**Middle East and Africa: Emerging Cloud Frontier**

The Middle East and Africa region is gradually emerging in the Immuno-oncology Assay market, currently holding about 4% of the global share. The Middle East and Africa (MEA) market for immuno-oncology assays is expanding significantly due to rising cancer rates, improvements in immunotherapy, and improved healthcare facilities. The market for cancer immunotherapy is expected to increase significantly in the larger MEA area.  Rising cancer incidence, increased use of immunotherapy over traditional therapies, and improvements in medical technology are some of the reasons for this growth. Leading the way in the adoption of cutting-edge cancer treatments are nations like South Africa, Saudi Arabia, and the United Arab Emirates.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Immuno-oncology Assay Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major players in the market include THERMO Fisher Scientific Inc, Qiagen, Merck KGAA, Sartorius Ag, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., ILLUMINA, INC,  Agilent Technologies Inc., Axion Biosystems, Inc, And Others. The Global Immuno-oncology Assay Market is a consolidated market due to increasing competition, acquisitions, mergers, and other strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

- In 2023, Agilent launched the SureSelect Cancer CGP Assay, an NGS-based solution for somatic variant profiling across a wide range of solid tumors.

## Report Scope

| Market Size 2024 | 3,954.87 (USD Million) |
| --- | --- |
| Market Size 2025 | 4,399.79 (USD Million) |
| Market Size 2035 | 12,406.18 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 10.92% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | THERMO Fisher Scientific Inc, Qiagen, Merck KGAA, Sartorius Ag, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., ILLUMINA, INC, Agilent Technologies Inc., Axion Biosystems, Inc, And Others |
| Segments Covered | By Product, By Assay Type, By Technology, By Application, By Indication, By End User |
| Key Market Opportunities | ·         Growing Geriatric Population ·         Technological Advancements |
| Key Market Dynamics | ·         Rising Incidence of Cancer ·         Government And Private Funding for Cancer Research |
| Countries Covered | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of Asia-Pacific, Brazil, Mexico, Argentina, Rest of South America, GCC Countries, South Africa, Rest of Middle East and Africa. |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Immuno-Oncology Assay Market by 2035?**
A: The projected market valuation for the Immuno-Oncology Assay Market is 49.96 USD Billion by 2035.

**Q: What was the market valuation of the Immuno-Oncology Assay Market in 2024?**
A: The overall market valuation was 29.39 USD Billion in 2024.

**Q: What is the expected CAGR for the Immuno-Oncology Assay Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Immuno-Oncology Assay Market during the forecast period 2025 - 2035 is 4.94%.

**Q: Which companies are considered key players in the Immuno-Oncology Assay Market?**
A: Key players in the market include Roche, Merck & Co, Bristol-Myers Squibb, Amgen, AstraZeneca, Novartis, Pfizer, GSK, and Eli Lilly.

**Q: What are the main types of assays in the Immuno-Oncology Assay Market and their projected valuations?**
A: Main types include Immune Cell Profiling Assays projected to reach 11.5 USD Billion, Cytokine Release Assays at 9.5 USD Billion, Tumor Mutation Burden Assays at 12.0 USD Billion, and Biomarker Discovery Assays at 16.96 USD Billion by 2035.

**Q: How do the technologies used in the Immuno-Oncology Assay Market compare in terms of projected growth?**
A: Technologies such as Next Generation Sequencing are projected to grow to 19.96 USD Billion, while Flow Cytometry and PCR-based Techniques are expected to reach 10.0 USD Billion and 12.0 USD Billion, respectively, by 2035.

**Q: What applications are driving growth in the Immuno-Oncology Assay Market?**
A: Applications such as Cancer Diagnosis and Clinical Trials are projected to grow to 13.0 USD Billion and 15.96 USD Billion, respectively, by 2035.

**Q: What is the projected growth for the end-use segments in the Immuno-Oncology Assay Market?**
A: End-use segments like Hospitals and Pharmaceutical Companies are expected to reach 16.0 USD Billion and 13.96 USD Billion, respectively, by 2035.

**Q: How does the Immuno-Oncology Assay Market's growth compare across different assay types?**
A: The Biomarker Discovery Assays segment appears to show the highest growth potential, projected to reach 16.96 USD Billion by 2035.

**Q: What factors are influencing the growth of the Immuno-Oncology Assay Market?**
A: Factors such as advancements in technology, increasing cancer prevalence, and the need for personalized medicine are likely influencing the growth of the Immuno-Oncology Assay Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immuno-oncology-assay-market-42957*